The biotech sector experiences notable deal activity and regulatory changes. Supernus Pharmaceuticals announced a $795 million acquisition of Sage Therapeutics, integrating its postpartum depression drug Zurzuvae into its CNS portfolio. AstraZeneca forged a $5.3 billion AI drug discovery partnership with CSPC Pharmaceutical. BioMérieux acquired Day Zero Diagnostics assets to bolster next-generation infectious disease testing. FDA leadership contemplates operational consolidations amid delayed drug reviews. Additionally, the UK government launched the 'Be Part of Research' app to expand clinical trial enrollment, while the MHRA implemented updated postmarket surveillance requirements.